Literature DB >> 1782302

Review article: assessment of drug therapy in inflammatory bowel disease.

H J Hodgson1, M Z Mazlam.   

Abstract

This review article surveys the clinical and laboratory parameters used to assess and quantitate inflammation in ulcerative colitis and Crohn's disease, with particular reference to their usage in controlled trials of drugs in inflammatory bowel disease.

Entities:  

Mesh：

Year:  1991        PMID： 1782302     DOI： 10.1111/j.1365-2036.1991.tb00525.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


  6 in total

1.  Medical management of Crohn's disease.

Authors:  Paul A Feldman; Daniel Wolfson; Jamie S Barkin
Journal:  Clin Colon Rectal Surg       Date:  2007-11

2.  Why measure C reactive protein?

Authors:  M Z Mazlam; H J Hodgson
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

3.  Health-related quality of life in inflammatory bowel disease.

Authors:  G M Eisen; R G Farmer
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

4.  Factor XIIIA subunit and Crohn's disease.

Authors:  M Hudson; A J Wakefield; R A Hutton; E A Sankey; A P Dhillon; L More; R Sim; R E Pounder
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

5.  Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease.

Authors:  J C Mansfield; M H Giaffer; C D Holdsworth
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

6.  Ficus pandurata Hance Inhibits Ulcerative Colitis and Colitis-Associated Secondary Liver Damage of Mice by Enhancing Antioxidation Activity.

Authors:  Weibo Dai; Xinyi Zhan; Weijie Peng; Xin Liu; Weiwen Peng; Quanxi Mei; Xianjing Hu
Journal:  Oxid Med Cell Longev       Date:  2021-12-18       Impact factor: 6.543
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.